Engineered immune cells take on deadly childhood brain cancer
NCT ID NCT07513194
First seen Apr 21, 2026 · Last updated May 01, 2026 · Updated 3 times
Summary
This early-phase trial tests a new treatment for children with a rare and aggressive brain tumor called atypical teratoid rhabdoid tumor (ATRT) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are genetically modified to recognize and attack the tumor, plus added signals to help them work longer. The main goals are to find a safe dose and see if the cells can shrink the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL TERATOID/RHABDOID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.